Jonathan Yap to Angiotensin-Converting Enzyme Inhibitors
This is a "connection" page, showing publications Jonathan Yap has written about Angiotensin-Converting Enzyme Inhibitors.
Connection Strength
0.375
-
Yap J, Keh YS, Shen T, Lam CSP, Chia SY, Jaufeerally FR, Ong W, Sim D, Ching CK. QRS duration and cardiovascular mortality in Asian patients with heart failure and preserved and reduced ejection fraction. Cardiol J. 2021; 28(1):166-169.
Score: 0.159
-
Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W, Richards AM, Voors A, Lam CS. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health. 2018 09; 6(9):e1008-e1018.
Score: 0.143
-
Chia YMF, Teng TK, Tay WT, Anand I, MacDonald MR, Yap J, Chandramouli C, Richards AM, Tromp J, Ouwerkerk W, Ling LH, Lam CSP. Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus. Eur J Heart Fail. 2019 05; 21(5):685-688.
Score: 0.037
-
Arnold SV, Yap J, Lam CSP, Tang F, Tay WT, Teng THK, McGuire DK, Januzzi JL, Fonarow GC, Masoudi FA, Kosiborod M. Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. Diabetes Obes Metab. 2019 02; 21(2):261-266.
Score: 0.036